{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/repl-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/repl-stock-analysis/data.json",
 "title": "Replimune (REPL) Stock Forecast & Price Target (2026)",
 "description": "Replimune Group, Inc. (REPL) stock: Healthcare, Biotechnology. $1.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Replimune Group, Inc. (REPL)",
 "published": "2026-07-20T09:31:07+00:00",
 "modified": "2026-09-12T01:46:22.044+00:00",
 "generated": "2026-09-12T23:56:04.475Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "REPL",
  "name": "Replimune Group, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.replimune.com"
 },
 "quote": {
  "price": 12.92,
  "previousClose": 13.24,
  "change": -0.32,
  "changePercent": -2.42,
  "open": 13.33,
  "high": 13.74,
  "low": 12.4,
  "volume": 4084167,
  "averageVolume": 2041557,
  "marketCap": 1217317671,
  "fiftyTwoWeekHigh": 16.33,
  "fiftyTwoWeekLow": 1.5,
  "marketOpen": false,
  "asOf": "2026-09-12T01:46:21.000Z"
 },
 "statistics": {
  "pe": -3.825443877270941,
  "eps": -3.15,
  "dividendYield": 0,
  "beta": 0.942,
  "priceToSales": null,
  "priceToBook": 10.27027,
  "revenueTtm": 0,
  "grossMargin": null,
  "returnOnEquity": -1.34286
 },
 "technicals": {
  "rsi": 33.33,
  "macd": 0.41,
  "sma50": 12.45,
  "sma200": 8.69,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 12.92,
  "analystTarget": 19.5,
  "analystCount": 8,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-12T01:46:21.000Z",
  "priceAtAnalysis": 12.92,
  "volatility": {
   "daily": 5.12,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 13.18,
  "aggressiveEntry": 12.92,
  "stopLoss": 15.31,
  "stopLossPercent": 16.21,
  "targets": [
   12.52,
   11.86,
   11.2
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 6.94,
    "base": 13.18,
    "upside90th": 25.02
   },
   {
    "year": 2028,
    "downside10th": 5.43,
    "base": 13.45,
    "upside90th": 33.28
   },
   {
    "year": 2029,
    "downside10th": 4.52,
    "base": 13.72,
    "upside90th": 41.63
   },
   {
    "year": 2030,
    "downside10th": 3.89,
    "base": 14,
    "upside90th": 50.43
   },
   {
    "year": 2031,
    "downside10th": 3.41,
    "base": 14.28,
    "upside90th": 59.85
   },
   {
    "year": 2032,
    "downside10th": 3.03,
    "base": 14.57,
    "upside90th": 70.01
   },
   {
    "year": 2033,
    "downside10th": 2.73,
    "base": 14.87,
    "upside90th": 81
   },
   {
    "year": 2034,
    "downside10th": 2.48,
    "base": 15.17,
    "upside90th": 92.9
   },
   {
    "year": 2035,
    "downside10th": 2.26,
    "base": 15.47,
    "upside90th": 105.79
   },
   {
    "year": 2036,
    "downside10th": 2.08,
    "base": 15.79,
    "upside90th": 119.76
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "REPL Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$13.33",
    "Day Range": "$12.40 to $13.74",
    "Prev Close": "$13.24",
    "Volume": "4.08M",
    "52-Week Range": "$1.50 to $16.33",
    "Market Cap": "$1.22B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis"
   ]
  },
  {
   "id": "financials",
   "title": "REPL Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, REPL beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "REPL Analysis",
   "text": [
    "Replimune Group, Inc. (REPL) is trading above its 50-day and 200-day moving averages ($12.45 and $8.69), suggesting a longer-term bullish trend. However, the stock is currently below its 20-day exponential moving average, indicating some short-term weakness. The Relative Strength Index (RSI) is at 33.33, signaling bearish momentum. Volume has been notably high, with the latest volume at 4,084,167, more than double the average volume of 2,041,557, suggesting significant investor interest and potential for volatility.",
    "Insiders have sold $2.6 million worth of stock across 43 transactions, with no reported insider purchases, indicating a potential lack of confidence in future performance.",
    "Replimune Group, Inc. has a current EPS of -$3.15, and recent earnings reports show inconsistent performance with a persistent negative EPS trend, raising concerns about profitability.",
    "The majority of Wall Street analysts maintain a 'Buy' rating, with a median price target of $19.50, suggesting an expected upside of 50.9% from the current price.",
    "Next year's revenue estimates show a projected growth of 490.00% to $50.2 million, indicating significant potential for future top-line expansion.",
    "The outlook for Replimune Group, Inc. (REPL) is cautiously bearish, primarily due to significant insider selling and a negative EPS. While Wall Street analysts maintain a 'Buy' consensus with a median price target of $19.50, the current price action and insider activity suggest potential headwinds. The company's forward revenue estimates show strong projected growth, but this must be weighed against the current profitability challenges and the signal from insider transactions."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the recent $2.6 million in net selling by insiders warrants significant attention and could signal a lack of confidence.",
     "The RSI is currently below 50, indicating bearish momentum. Investors should watch for a potential bounce if the RSI moves back above 50, but the current trend is negative.",
     "Given the negative EPS and mixed earnings performance, investors should consider the company's cash burn rate and long-term funding strategy."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Significant Insider Selling",
     "text": "Insiders have sold $2.6 million worth of stock across 43 transactions, with no reported insider purchases, indicating a potential lack of confidence in future performance.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Negative EPS Trend",
     "text": "Replimune Group, Inc. has a current EPS of -$3.15, and recent earnings reports show inconsistent performance with a persistent negative EPS trend, raising concerns about profitability.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Positive Analyst Sentiment",
     "text": "The majority of Wall Street analysts maintain a 'Buy' rating, with a median price target of $19.50, suggesting an expected upside of 50.9% from the current price.",
     "source": "Wall Street Analysts"
    },
    {
     "type": "Bullish",
     "title": "Strong Forward Revenue Growth Projection",
     "text": "Next year's revenue estimates show a projected growth of 490.00% to $50.2 million, indicating significant potential for future top-line expansion.",
     "source": "Revenue Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Replimune Group, Inc. (REPL) exhibits a negative EPS of -$3.15, making traditional P/E ratio analysis inapplicable. The company's revenue growth is not provided, but forward revenue estimates for next year show a substantial projected increase of 490.00% to $50.2 million, albeit with a capped average that suggests potential outlier skew. The current price of $12.92 is below the median Wall Street price target of $19.50, implying a potential upside of 50.9%, but this is contrasted by significant insider selling.",
    "Replimune Group, Inc. (REPL) most recently reported an EPS of -$0.72, beating the estimated -$0.77 by 6.49%, though the stock saw a -2.27% price change. Prior to this, the company missed estimates in the June 2026 quarter. The March 2026 quarter showed a significant EPS beat of 11.86%, but the stock price reacted negatively. Overall, earnings performance has been inconsistent, with a mix of beats and misses, and a persistent negative EPS trend.",
    "The primary risk for Replimune Group, Inc. (REPL) stems from significant insider selling totaling $2.6 million, indicating a lack of confidence from management. The company also carries a negative EPS of -$3.15, raising concerns about its profitability and financial sustainability. While Wall Street maintains a 'Buy' consensus, the bearish technical momentum and insider activity present considerable downside risks."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "1.22B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-3.15"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "16.33"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "1.50"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bearish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($12.45) above the 200-day SMA ($8.692), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "33.33"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.41"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "12.45"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "8.69"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.03",
    "Correlation with Nasdaq 100 (QQQ)": "+0.05",
    "Correlation with Bitcoin (BTC)": "-0.05",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "REPL Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (33.3) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$12.52",
    "TARGET 2": "$11.86",
    "TARGET 3": "$11.20",
    "STOP LOSS": "$15.31"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-2.66%",
    "Average Feb return": "-5.51%",
    "Average Mar return": "-8.55%",
    "Average Apr return": "+3.55%",
    "Average May return": "+28.66%",
    "Average Jun return": "+20.67%",
    "Average Jul return": "-6.38%",
    "Average Aug return": "+2.51%",
    "Average Sep return": "-6.90%",
    "Average Oct return": "+26.58%",
    "Average Nov return": "+2.39%",
    "Average Dec return": "-8.38%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "5.12%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in REPL in July 2018 would be worth about $8,522 today, compared with about $27,327 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REPL today could grow to about $12,218 by 2036 in the base case, with a bull case near $92,695 and a bear case around $1,610. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "REPL Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $14.00 for REPL by 2030 in the base case, from $12.92 today (1.1x over 4 years). The downside path ends near $3.89. These are outcomes of a Monte Carlo simulation run on REPL's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using REPL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "REPL simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$6.94",
        "$13.18",
        "$25.02"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$5.43",
        "$13.45",
        "$33.28"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$4.52",
        "$13.72",
        "$41.63"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$3.89",
        "$14.00",
        "$50.43"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$3.41",
        "$14.28",
        "$59.85"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$3.03",
        "$14.57",
        "$70.01"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$2.73",
        "$14.87",
        "$81.00"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$2.48",
        "$15.17",
        "$92.90"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$2.26",
        "$15.47",
        "$106"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$2.08",
        "$15.79",
        "$120"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "PFE Pfizer Inc. NYSE $27.72 +0.25%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $4.02 -2.90%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "UNH UnitedHealth Group Inc. NYSE $379.09 -2.37%",
     "url": "https://clearank.com/stock/unitedhealth-group-unh/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $881.51 +0.07%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "ZTS Zoetis Inc. NYSE $72.97 +0.15%",
     "url": "https://clearank.com/stock/zts-stock-analysis/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.78 +0.08%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $261.77 +1.74%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "CVS CVS Health Corporation NYSE $94.66 -0.66%",
     "url": "https://clearank.com/stock/cvs-health-cvs/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "SLV vs SIVR Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/slv-vs-sivr/"
    },
    {
     "text": "SOFI vs AFRM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/sofi-vs-afrm/"
    },
    {
     "text": "CARR vs TT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/carr-vs-tt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "REPL Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$2.6M",
    "Insiders": "7",
    "Avg Transaction": "$107.7K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in REPL",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Dec 9, 2020",
       "cells": [
        "RHODES JASON P Director",
        "Sell",
        "217.4K",
        "$10.0M"
       ]
      },
      {
       "label": "Dec 22, 2020",
       "cells": [
        "COFFIN ROBERT President",
        "Sell",
        "220.0K",
        "$8.8M"
       ]
      },
      {
       "label": "Dec 14, 2020",
       "cells": [
        "RHODES JASON P Director",
        "Sell",
        "103.7K",
        "$4.5M"
       ]
      },
      {
       "label": "Jul 9, 2020",
       "cells": [
        "COFFIN ROBERT President",
        "Sell",
        "169.8K",
        "$3.8M"
       ]
      },
      {
       "label": "Sep 17, 2021",
       "cells": [
        "OMEGA FUND IV, LP. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "100.0K",
        "$3.3M"
       ]
      },
      {
       "label": "Dec 17, 2020",
       "cells": [
        "RHODES JASON P Director",
        "Sell",
        "65.0K",
        "$2.7M"
       ]
      },
      {
       "label": "Jan 22, 2021",
       "cells": [
        "COFFIN ROBERT President",
        "Sell",
        "60.0K",
        "$2.7M"
       ]
      },
      {
       "label": "Jan 19, 2021",
       "cells": [
        "ESPOSITO PAMELA Officer",
        "Sell",
        "55.0K",
        "$2.4M"
       ]
      },
      {
       "label": "Jan 19, 2021",
       "cells": [
        "ESPOSITO PAMELA Officer",
        "Sell",
        "55.0K",
        "$2.4M"
       ]
      },
      {
       "label": "Jan 19, 2021",
       "cells": [
        "ASTLEY-SPARKE PHILIP Chief Executive Officer",
        "Sell",
        "50.0K",
        "$2.2M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Replimune+Group%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Replimune Group, Inc.'s current stock price and outlook?",
   "answer": "Replimune Group, Inc. (REPL) is currently trading at $12.92. The outlook is mixed, with a 'Buy' consensus from Wall Street analysts and a median price target of $19.50, but tempered by significant insider selling and bearish technical momentum."
  },
  {
   "question": "Is Replimune Group, Inc. stock a buy or sell?",
   "answer": "Based on the current data, the consensus rating is 'Sell' with a score of 18. While Wall Street analysts largely rate it a 'Buy', significant insider selling and negative EPS trends suggest caution."
  },
  {
   "question": "What are the key risks facing Replimune Group, Inc.?",
   "answer": "The primary risks include substantial insider selling totaling $2.6 million, a negative EPS of -$3.15, and bearish momentum indicated by the RSI. These factors outweigh the positive sentiment from Wall Street analysts."
  },
  {
   "question": "How has Replimune Group, Inc. performed in recent earnings reports?",
   "answer": "Replimune Group, Inc. (REPL) recently beat EPS estimates by 6.49% in its latest report, but the stock price declined. Prior quarters have shown inconsistent performance with both beats and misses, and a persistent negative EPS trend."
  },
  {
   "question": "What is the technical outlook for Replimune Group, Inc. stock?",
   "answer": "Technically, REPL is trading above its 50-day and 200-day moving averages ($12.45 and $8.69) but below its 20-day EMA. The RSI is in bearish territory at 33.33, indicating bearish momentum, despite the longer-term moving average support."
  },
  {
   "question": "What is Replimune Group, Inc.'s revenue growth projection?",
   "answer": "However, forward estimates for next year project significant growth of 490.00% to $50.2 million, though this average may be skewed by outliers."
  },
  {
   "question": "What is Replimune Group, Inc.'s stock forecast for 2030?",
   "answer": "According to Monte Carlo simulations, Replimune Group, Inc.'s stock forecast for 2030 shows a base case price of $14, with a downside projection of $3.89 and an upside projection of $50.43. These are simulation outcomes, not guarantees."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$27.72",
    "change": "+0.25%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$4.02",
    "change": "-2.90%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "UNH",
    "name": "UnitedHealth Group Inc. NYSE",
    "price": "$379.09",
    "change": "-2.37%",
    "url": "https://clearank.com/stock/unitedhealth-group-unh/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$881.51",
    "change": "+0.07%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "ZTS",
    "name": "Zoetis Inc. NYSE",
    "price": "$72.97",
    "change": "+0.15%",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.78",
    "change": "+0.08%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$261.77",
    "change": "+1.74%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "CVS",
    "name": "CVS Health Corporation NYSE",
    "price": "$94.66",
    "change": "-0.66%",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   }
  ],
  "comparisons": [
   {
    "ticker": "SLV vs SIVR Comparison",
    "name": "",
    "url": "https://clearank.com/compare/slv-vs-sivr/"
   },
   {
    "ticker": "SOFI vs AFRM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/sofi-vs-afrm/"
   },
   {
    "ticker": "CARR vs TT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/carr-vs-tt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SYY",
    "text": "Sysco Corp.",
    "url": "https://clearank.com/stock/syy-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "DELL",
    "text": "↑ 11.98%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   },
   {
    "ticker": "NEAR/USD",
    "text": "↓ 10.99%",
    "url": "https://clearank.com/crypto/near-protocol-near-usd/"
   },
   {
    "ticker": "IMSR",
    "text": "↓ 9.79%",
    "url": "https://clearank.com/stock/terrestrial-energy-imsr/"
   },
   {
    "ticker": "ETHFI/USD",
    "text": "↑ 9.56%",
    "url": "https://clearank.com/crypto/ethfi-usd-crypto-analysis/"
   },
   {
    "ticker": "OKLO",
    "text": "↓ 9.18%",
    "url": "https://clearank.com/stock/oklo-inc/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "text": "Recursion",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "text": "Viking Therapeutics Inc",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/repl-replimune-group-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/repl-replimune-group-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Replimune Group (REPL) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/repl-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/repl-stock-analysis/",
        "name": "Replimune (REPL) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/repl-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/repl-stock-analysis/",
     "name": "Replimune (REPL) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:31:07+00:00",
     "dateModified": "2026-09-12T01:46:22+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/repl-replimune-group-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/repl-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Replimune (REPL) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-20T09:31:07+00:00",
     "dateModified": "2026-09-12T01:46:22+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Replimune Group, Inc. (REPL) stock: Healthcare, Biotechnology. $1.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Replimune (REPL) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/repl-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/repl-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/repl-replimune-group-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/repl-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Replimune Group, Inc. (REPL)",
   "tickerSymbol": "REPL",
   "url": "https://clearank.com/stock/repl-stock-analysis/",
   "description": "AI-powered financial analysis for Replimune Group, Inc. (REPL) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 12.92,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/repl-stock-analysis/",
    "priceValidUntil": "2026-09-13"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Replimune Group, Inc.'s current stock price and outlook?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Replimune Group, Inc. (REPL) is currently trading at $12.92. The outlook is mixed, with a 'Buy' consensus from Wall Street analysts and a median price target of $19.50, but tempered by significant insider selling and bearish technical momentum."
     }
    },
    {
     "@type": "Question",
     "name": "Is Replimune Group, Inc. stock a buy or sell?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on the current data, the consensus rating is 'Sell' with a score of 18. While Wall Street analysts largely rate it a 'Buy', significant insider selling and negative EPS trends suggest caution."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks facing Replimune Group, Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks include substantial insider selling totaling $2.6 million, a negative EPS of -$3.15, and bearish momentum indicated by the RSI. These factors outweigh the positive sentiment from Wall Street analysts."
     }
    },
    {
     "@type": "Question",
     "name": "How has Replimune Group, Inc. performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Replimune Group, Inc. (REPL) recently beat EPS estimates by 6.49% in its latest report, but the stock price declined. Prior quarters have shown inconsistent performance with both beats and misses, and a persistent negative EPS trend."
     }
    },
    {
     "@type": "Question",
     "name": "What is the technical outlook for Replimune Group, Inc. stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Technically, REPL is trading above its 50-day and 200-day SMAs but below its 20-day EMA. The RSI is in bearish territory at 33.33, indicating bearish momentum, despite the longer-term moving average support."
     }
    },
    {
     "@type": "Question",
     "name": "What is Replimune Group, Inc.'s revenue growth projection?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "However, forward estimates for next year project significant growth of 490.00% to $50.2 million, though this average may be skewed by outliers."
     }
    },
    {
     "@type": "Question",
     "name": "What is Replimune Group, Inc.'s stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "According to Monte Carlo simulations, Replimune Group, Inc.'s stock forecast for 2030 shows a base case price of $14, with a downside projection of $3.89 and an upside projection of $50.43. These are simulation outcomes, not guarantees."
     }
    }
   ]
  }
 ]
}